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Abstract: A number of 50 -O-fatty acyl derivatives of 30 -fluoro-20 ,30 -dideoxythymidine (FLT, 1) were
synthesized. These conjugates were evaluated for their potential as topical microbicides with anti-HIV
activity against cell-free (X4 and R5), cell-associated, and multidrug-resistant viruses. Compared
to FLT and 30 -azido-20 ,30 -dideoxythymidine (AZT), 50 -O-(12-azidododecanoyl) (5), 50 -O-myristoyl
(6), and 50 -O-(12-thioethyldodecanoyl) (8) derivatives of FLT were found to be more active against
both cell-free viruses (lymphocytotropic and monocytotropic strains) with EC50 values of 0.4 µM,
1.1 µM, and <0.2 µM, respectively, as well as cell-associated virus with EC50 values of 12.6, 6.4, and
2.3 µM, respectively. Conjugates 5, 6, and 8 exhibited >4 and >30 times better antiviral index than
FLT and AZT, respectively. Conjugates 5 and 8 were significantly more potent than FLT against
many multidrug-resistant strains. A comparison of the anti-HIV activity with the corresponding
non-hydrolyzable ether conjugates suggested that ester hydrolysis to FLT and fatty acids is critical
to enable anti-HIV activity. Cellular uptake studies were conducted using fluorescent derivatives
of FLT attached with 5(6)-carboxyfluorescein through either β-alanine (23) or 12-aminododecanoic
acid (24) spacers. The lipophilic fluorescent analog with a long chain (24) showed more than 12 times
higher cellular uptake profile than the fluorescent analog with a short chain (23). These studies
further confirmed that the attachment of fatty acids improved the cellular uptake of nucleoside
conjugates. In addition, 5, 6, and 8 were the least cytotoxic and did not alter vaginal cell and sperm
viability compared to the positive control, a commercial topical spermicide (N-9), which significantly
decreased sperm and vaginal cell viability inducing the generation of proinflammatory cytokines.

published maps and institutional affiliations.
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1. Introduction
In June 1981, the very first case of acquired immunodeficiency syndrome (AIDS) in the
United States was identified to be caused by the human immunodeficiency virus (HIV) [1].
For the next several years, AIDS was considered as an untreatable condition, tagging it as
a death sentence. Today, HIV/AIDS has claimed more than 36 million lives worldwide
according to UNAIDS 2022 Fact Sheet.
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Significant research across the world resulted in the development of antiretroviral
drugs for HIV. Using Highly Active Anti-Retroviral Therapy (HAART) on a daily basis,
the viral content in an HIV-positive patient can be reduced to an undetectable level of HIV,
which in turn significantly reduces transmission [2–4]. The global fight against HIV has
been very effective; however, HIV is still slowly spreading. Recent experiences have taught
us the value of protecting ourselves from other deadly viruses [5,6]. With 38 million people
globally living with HIV and >1.7 million newly infected HIV cases reported in 2019, the
transmission of HIV infection cannot be ignored [7]. Preventing viral spread will play
a crucial role if the Sustainable Development Goal (United Nations) of ending the AIDS
epidemic is to be met by the targeted deadline of 2030 [7,8]. Therefore, we are committed to
the design and evaluation of fatty acid esters of nucleoside analogs for topical application
and anti-HIV microbicides to prevent viral transmission. Microbicides are compounds that
are topically applied to the vagina or rectum and may confer protection against sexually
transmitted diseases including HIV.
We have previously reported a number of 50 -O-fatty acyl derivatives of alovudine (FLT,
0
3 -fluoro-20 ,30 -dideoxythymidine, 1) and Zidovudine (AZT, 30 -azido-20 ,30 -dideoxythymidine)
that exhibited a better and wider activity profile than FLT and AZT, respectively [9,10].
Among these, three FLT conjugates of myristic acid, 12-azidododecanoic acid, and 13thiapentadecanoic acid provided promising results against the X4 and R5 strains of HIV
through the synergistic inhibition of both cell-free virus and cell-associated virus.
We hypothesized that the attachment of nucleoside analogs to the long-chain myristic
acid analogs enhances their lipophilicity and thus their cellular uptake. Once the conjugate enters the cells, it is expected to be hydrolyzed by esterase and generate two active
molecules: (i) a nucleoside analog, targeting reverse transcriptase (RT), and (ii) a fatty
acid targeting N-myristoyl transferase (NMT) enzymes. Nucleoside analogs are among
the first class of drugs approved to treat HIV through RT inhibition. In addition, fatty
acid analogs moderately contribute to the inhibition of NMT, which is involved in catalyzing the myristoylation of several proteins in the HIV life cycle (e.g., capsid protein
p17, Pr160gag-pol , Pr55gag , p27nef ) [11,12]. For example, 12-thioethyldodecanoic acid was
moderately active (EC50 = 9.4 µM) against HIV-infected T4 lymphocytes [13]. Using these
three fatty acids, we synthesized several ester conjugates of anti-HIV reverse transcriptase inhibitors (NRTIs) such as 20 ,30 -didehydro-20 ,30 -dideoxythymidine (stavudine, d4T),
20 ,30 -dideoxy-30 -thiacytidine (lamivudine, 3TC), and 20 ,30 -dideoxy-5-fluoro-30 -thiacytidine
(emtricitabine, FTC), which showed enhanced activity against X4, R5, cell-associated,
and/or multidrug-resistant virus when compared to their parent nucleosides [14–17].
While FLT displays similar pharmacokinetic parameters to AZT, it is significantly
more potent than AZT [18–20]. FLT was under clinical evaluation from 1990 to 1992.
The studies were stopped after FLT failed phase II clinical trials because of the observed
hematological toxicities including neutropenia, leucopenia, and anemia [21–23]. A number
of phosphoramidates and phosphorodiamidates of FLT have also been synthesized and
evaluated, showing sub-micromolar inhibition of HIV-1 and HIV-2 replication and activity
in the thymidine kinase-negative cell models [24]. There has been a resurgent interest in
studies using 18 F-FLT in PET imaging for cancer detection [25–27]. We have also previously
shown that the N-myristoylglutamic acid derivative of FLT generated an organogel that
could be used in the design of microbicidal gels [28]. Thus, we evaluated the fatty acyl ester
of FLT as alternative anti-HIV microbicidal agents and preventive tools to avoid extensive
in vivo systemic toxicity associated with several nucleoside analogs.
As described above, the replication of HIV-1 can be inhibited by heteroatom-containing
analogs of myristic acid without accompanying cellular toxicity [29,30]. It has been previously reported that several fatty acids such as 2-methoxydodecanoic acid, 4-oxatetradecanoic
acid, and 12-thioethyldodecanoic acid reduce HIV-1 replication in acutely infected Tlymphocytes. At N-terminal glycine, viral proteins (gag and nef) are covalently attached to
myristic acid in the presence of NMT. Myristic acid attachment makes the proteins more
hydrophobic, which improves the protein–protein and protein–membrane interactions [31].
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to assess this activity, FLT and AZT were only inconsistently and moderately active against
the cell-associated virus. The difference in the activity of fatty acyl derivatives of FLT
compared to each other and FLT may be due to their differences in the rate of uptake and
intracellular hydrolysis.
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Table 3. Comparison of the anti-HIV activities of fatty acyl derivatives of AZT and FLT with the
corresponding physical mixtures of AZT or FLT + fatty acids.
Chemical Name

Cytotoxicity a
EC50 b (µM)

(X4) c EC50 (µM)

(R5) d EC50 (µM)

(CA) e EC50 (µM)

FLT (1)
AZT (2)
C13 H27 -COO-FLT (6)
C13 H27 -COOH + FLT (50:50) (25)
C13 H27 -COO-AZT (7)
C13 H27 -COOH + AZT (50:50) (26)
Br-C11 H22 -COO-AZT (12)
Br-C11 H22 -COOH + AZT (50:50) (27)

>410
>374
606.0
>106
>629
>202
>190
>183

0.8
10.9
0.7
<0.2
3.1
1.4
14.8
34.8

0.4
14.2
1.1
0.8
5.0
46.2
4.6
8.8

>410
>374
6.4
33.0
>629
>202
>190
>183

a

Cytotoxicity assay; b 50% Effective concentration; c Viral entry inhibition assay (lymphocytotropic strain); d Viral
entry inhibition assay (monocytotropic strain); e Cell-to-cell transmission assay (IIIB). The data represents the
average of triplicate experiments.

Table 4. Anti-HIV evaluation against wild type clinical isolates and resistant virus a .
Compd.

Virus

Clade/Resistance

IC50 b
(nM)

IC90 c
(nM)

FLT

94US3393IN
98USMSC5016
A-17 MDR
4755-5 MDR
94US3393IN
98USMSC5016
A-17 MDR
4755-5 MDR
94US3393IN
98USMSC5016
A-17 MDR
4755-5 MDR

B-Wild Type
C-Wild Type
B-NNRTI
B-MDR
B-Wild Type
C-Wild Type
B-NNRTI
B-MDR
B-Wild Type
C-Wild Type
B-NNRTI
B-MDR

2.0
2.0
26.0
107.3
1.1
2.1
4.4
39.6
0.6
1.0
13.6
111.5

20.4
12.3
87.2
1065.0
6.4
8.6
14.1
507.2
10.3
8.2
45.7
662.2

5

8

a

Multi-round infection assay using HIV-1 clinical isolates [wild type R5 clones = 94US3393IN (B subtype) and
98USMSC5016 (C subtype) and multi-drug resistant clones = 4755−5 and A17] HIV-1 clinical isolates. b IC50 = The
minimum drug concentration that inhibits HIV-induced cytopathic effect by 50%, calculated by using a regression
analysis program for semilog curve fitting; c IC90 = The minimum drug concentration that inhibits HIV-induced
cytopathic effect by 90%, calculated by using a regression analysis program for semilog curve fitting). The data
represent the average of triplicate experiments.

By design, the ester moiety in the conjugates needs to be hydrolyzed to render parent
nucleosides and fatty acids to produce anti-HIV activity. The anti-HIV activities of 50 -O-ether
substituted FLT and AZT (3 and 4, Scheme 2) with a stable tetradecanyl (myristyl) group were
compared with hydrolyzable 50 -O-ester substituted FLT and AZT (6 and 7). Both ether
derivatives (3 and 4) were significantly less potent than the corresponding ester derivatives
(6 and 7). These data demonstrate that the ester bonds are important in enabling the
anti-HIV activity of the fatty acyl ester derivatives of FLT and AZT (5–18). Results indicated
that the anti-HIV activity of these conjugates were not due to their incorporation in the HIV
membrane and/or to a detergent effect, as lipophilic ether derivatives, 3 and 4 were not
potent anti-HIV agents.
Table 3 displays the anti-HIV activity of FLT or AZT, their equimolar mixture with
fatty acids (25–27), and selected ester conjugates (6, 7, and 12). All ester conjugates were
more active than their corresponding physical mixtures. The 50 -O-myristoyl FLT (6) was
more active and consistent in displaying antiviral activity against the cell-associated virus
than FLT and its physical mixture with myristic acid (25) (myristic acid and FLT (50:50).
This physical mixture of myristic acid and FLT (25, EC50 = 33 µM) exhibited a 5.2-times
lower potency against the cell-associated virus than (6, EC50 = 6.4 µM), suggesting that
conjugation is required for the efficient inhibition of cell-associated virus.

Molecules 2022, 27, 3352

7 of 17

These data indicate that the nature of the substituent(s) on the fatty acid chain and
the presence of fluorine or azide at the 30 -position are determinants of anti-HIV activity.
The lower activities of certain analogs may be due to the slower regeneration of the parent
nucleoside or slower cellular uptake. The ability of fatty acyl derivatives of FLT such as
5 and 8 control the cell-to-cell transmission of the virus, whereas FLT is not active at all,
which could be due to their higher cellular uptake compared to FLT in the infected cells and
enhanced the delivery of FLT in infected cells. Additionally, 5 and 8 also release myristic
acid analogs intracellularly that can potentially inhibit the post-translation modification of
viral proteins such as protein myristoylation, and eventually block the release of new virus
to infect other cells.
2.3.2. Anti-HIV Activities against MDR Isolates
Based on a preliminary screening, conjugates 5 and 8 were evaluated for their ability
to inhibit a drug-resistant virus in a peripheral blood mononuclear cell (PBMC) assay.
In this assay, FLT, 5, and 8 were tested against B- and C-wild type and A-17 and 4755–5
multidrug-resistant (MDR) clinical isolates of HIV-1, where compounds were incubated
with PBMCs for 6 h and then washed off before the addition of the virus and further culture
for 7 days. Results indicated that FLT derivatives 5 (IC50 = 1.1 and 2.1 nM) and 8 (IC50 = 0.6
and 1.0 nM) moderately improved the overall activity against B- and C-wild type virus,
respectively, in comparison to the FLT (IC50 = 2.0 and 2.0 nM). More importantly, 5 and 8
were significantly more active against the drug-resistant virus compared to FLT (Table 4).
In comparison to FLT (IC50 = 26.0 and 107.3 nM), compound 5 (IC50 = 4.4 and 39.6 nM) was
at least 6- and 2.7-fold more potent against the A-17 and 4755-5 strains of the MDR virus,
respectively. However, compound 8 (IC50 = 13.6 and 111.5 nM) was only twice as active
against the A-17 MDR strain of the virus and was equally active against the 4766-5 MDR
strain of the virus. These results indicate that 5 and 8 offer better activity against the wild
type as well as drug-resistant virus, where FLT fails as a parent nucleoside.
2.3.3. Cellular Uptake Study
The cellular uptake profile of 50 -O-fatty acyl derivatives were investigated in comparison with FLT to support the hypothesis of improved antiviral activity for conjugates such as
5 and 8. FLT attached to FAM through β-alanine (23, shorter linker) was used as a control FLT
analog. FLT attached to FAM through 12-aminododecanoic acid (24, longer linker) was used
as an analog of 30 -fluoro-20 ,30 -dideoxy-50 -O-(12-azidododecanoyl)thymidine (5) and other fatty
acid ester conjugates of FLT. 30 -Fluoro-20 ,30 -dideoxy-50 -O-(12-aminododecanoyl)thymidine
(22) showed anti-HIV activities comparable to other fatty acyl derivatives of FLT (Table 2).
The fluorescein-labeled fatty acyl ester derivative of FLT (24) showed a slightly lower anti-HIV
activity when compared with the unsubstituted 12-aminododecanoyl derivative (22).
Human T-lymphoblastoid cells (CCRF-CEM, ATCC No. CCL-119) were used in the
study and were grown to 70% confluency in the culture media. The cells were incubated
with the fluorescein-substituted conjugates (23 and 24) for different time periods (Figure 1A)
and in incremental concentrations of 24 (Figure 1B). DMSO and FAM were used as a control
for the study. The cells were analyzed by flow cytometry (FACSCalibur: Becton Dickinson)
using the FITC channel and CellQuest software. The data presented are based on the mean
fluorescence signal for 10,000 cells collected. All of the assays were carried out in triplicate.
In the first assay, the CCRF-CEM cells were incubated with 10 µM of the compounds
for different time periods (0.5 h, 1 h, 2 h, 4 h, and 8 h, Figure 1A). Compound 24 exhibited
a 10–15-fold higher cellular uptake than that of 23 and FAM alone. The results clearly
indicate that the presence of a long-chain enhances the cellular uptake of FLT by increasing
the lipophilicity. The continuous incubation of cells with compounds up to 8 h did not
show a significant difference in the cellular uptake, suggesting that most of the fatty acyl
ester derivative is absorbed in the cells within the first 60 min of incubation.
In the second assay, cells were incubated with different concentrations (5, 10, 20,
40, and 100 µM) of 24 for 1 h (Figure 1B). The data suggest that the cellular uptake was
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concentration-dependent. In the third assay, we used trypsin wash to confirm that the
enhanced uptake of 24 was not due to the absorption on the cell membrane surface. In this
assay, cells were incubated with 10 µM of DMSO, FAM, 23, and 24 for 1 h and then treated
with trypsin for 5 min to wash the adsorbed molecules (if any) from the cell membrane. The
cellular uptake studies after trypsin treatment showed that the cellular uptake of 24 was
still about 5 times higher than those of the control compounds, FAM and 23 (Figure 1C),
suggesting that the higher cellular uptake of 24 was not due to artificial absorption to the
cell membrane.
Cells incubated with 10 µM of DMSO, FAM, 23 and 24 for 1 h were used for real time
fluorescence microscopy using transmitted light microscopy equipped with a differentialinterference contrast method and an Achroplan 40× objective. Cells showed no significant
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In the first assay, the CCRF-CEM cells were incubated with 10 μM of the compounds
2.3.4. Cell Viability Study
for different time periods (0.5 h, 1 h, 2 h, 4 h, and 8 h, Figure 1A). Compound 24 exhibited
Cell viability
study
was performed
to that
analyze
theand
effect
of FAM,
andresults
24 on the
live
a 10–15-fold
higher
cellular
uptake than
of 23
FAM
alone.23,The
clearly
cells. The CCRF-CEM cells were incubated with 10 µM of the compounds and mixed with
indicate
that the presence of a long-chain enhances the cellular uptake of FLT by increastrypan blue (0.1%) to color the dead cells. The percentage of viability was calculated by
ing the lipophilicity. The continuous incubation of cells with compounds up to 8 h did not
show a significant difference in the cellular uptake, suggesting that most of the fatty acyl
ester derivative is absorbed in the cells within the first 60 min of incubation.
In the second assay, cells were incubated with different concentrations (5, 10, 20, 40,
and 100 μM) of 24 for 1 h (Figure 1B). The data suggest that the cellular uptake was con-
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using Cellometer Auto T.4 (Nexcelom Bioscience). It was observed that at least 80% of the
cells were viable in the presence of the compounds in a 24 h incubation period (Supporting
Materials, Figure S1).
2.3.5. Effect of Conjugates on Sperm Viability and Mobility
In this study, several fatty acyl conjugates of nucleosides (5–8, 10–12, 15, and 16) were
tested for their spermicidal activities. In a dose–response study to evaluate spermicidal
activity, none of the derivatives characterized in this study showed any significant sperm
immobilizing or spermicidal activity, even at their maximum concentrations (1 mg/mL).
Detailed data analysis is available in the Supplementary Materials (Figure S2).
2.3.6. Effect of Conjugates on Vaginal Cell Viability
A commercially used spermicidal agent (N-9) and conjugate cytotoxicity was evaluated
using immortalized human vaginal cells (VK-2/E6E7). Conjugates 5, 6, and 8 showed
significantly less cytotoxicity and proinflammatory potential than N-9 (Figure 2), while
displaying potent anti-HIV activity. In contrast to N-9 (used as positive control), 5, 6, and 8
did not show significant cytotoxic effects during a 6 h incubation at multiple concentrations
(ranging from 31–1000 µg/mL) (Figure 2A). The vaginal cell viability decreased after
incubating cells with N-9, especially at higher concentrations. Observed cytotoxicity from
N-9 could be correlated with the generation of higher levels of cytokines by N-9. It was
found that N-9 produced a very high concentration of proinflammatory cytokines such
as IL-1α in comparison to the conjugates. Unlike N-9, compounds 5, 6, and 8 did not
induce the release of IL-1α, a powerful proinflammatory cytokine (Figure 2B). These results
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3.1. Materials
3.1. Materials
For the initial work, FLT was synthesized at a 5 g scale according to the previously
For the initial work, FLT was synthesized at a 5 g scale according to the previously
reported method [33]. More FLT and AZT were purchased from Euro Asia Tran Continental
reported
method
[33]. More FLT
and AZT
were
purchased
from
Euro Asia Tran Conti(Bombay, India)
for large-scale
synthesis
of the
ester
conjugates.
12-Bromododecanoic
nental
(Bombay,
India)
for
large-scale
synthesis
of
the
ester
conjugates.
12-Bromododecaacid was purchased from the Sigma Aldrich Chemical Co (St. Louis, MO,
USA). 5(6)noic
acid
was
purchased
from
the
Sigma
Aldrich
Chemical
Co
(St.
Louis,
MO,
USA).
5(6)Carboxyfluorescein (FAM) was purchased from Novabiochem-Millipore (Burlington,
MA,
Carboxyfluorescein
(FAM) was
purchased
from
Novabiochem-Millipore
(Burlington,
USA).
All of the other reagents
including
solvents
were
purchased from Fisher Scientific
MA,
USA).
All
of
the
other
reagents
including
solvents
were
purchased
from
Fisher Sci(Hampton, NI, USA). Human T-lymphoblastoid cells (CCRF-CEM, ATCC No. CCL-119),
entific (Hampton, NI, USA). Human T-lymphoblastoid cells (CCRF-CEM, ATCC No.
CCL-119), the HeLa (human cervical carcinoma: ATCC CCL-2.1) cell line, and human vaginal cells (VK-2/E6E7, ATCC CRL-2616) were purchased from ATCC (Manassas, VA,
USA).
The products were purified on a Phenomenex®Gemini 10 μm ODS reversed-phase
column (2.1 × 25 cm) with a Hitachi HPLC system using a gradient increment in the ace-
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the HeLa (human cervical carcinoma: ATCC CCL-2.1) cell line, and human vaginal cells
(VK-2/E6E7, ATCC CRL-2616) were purchased from ATCC (Manassas, VA, USA).
The products were purified on a Phenomenex® Gemini 10 µm ODS reversed-phase
column (2.1 × 25 cm) with a Hitachi HPLC system using a gradient increment in the
acetonitrile (0.1%TFA) concentration from 0 to 100% in 45 min at a constant flow rate of
17 mL/min. The purity of the compounds was confirmed by using an analytical Hitachi
analytical HPLC system on a C18 column (Grace Allsphere ODS 2–3 µ, 150 × 4.6 mm) using
a gradient system (water:acetonitrile 30:70 v/v) at a constant flow rate of 1 mL/min with a
UV detection at 265 nm. The chemical structures of the final products were characterized
by nuclear magnetic resonance spectrometry (1 H NMR and 13 C NMR) determined on
a Bruker NMR spectrometer (400 MHz, Daltonik, Bremen, Germany) and confirmed by
a high-resolution PE Applied Biosystems Mariner API time-of-flight electrospray mass
spectrometer (Waltham, MA, USA). Chemical shifts are reported in parts per millions (ppm).
For cellular uptake studies, cells were analyzed by flow cytometry (FACSCalibur: Becton
Dickinson, San Jose, CA, USA) using the FITC channel and CellQuest software 7.5.3 (Becton
Dickinson, San Jose, CA, USA). Cell-viability studies were conducted using Cellometer
Auto T.4 (Nexcelom Biosciences, Lawrence, MA, USA). The real-time microscopy in a live
CCRF-CEM cell line with or with compounds was imaged using a ZEISS (Jena, Germany)
Axioplan 2 light microscope equipped with transmitted light microscopy with a differential–
interference contrast method and an Achroplan 40× objective.
3.2. Chemistry
General procedure for the synthesis of 50 -O-(fatty ether) derivatives of FLT and AZT:
(3) and 30 -azido-20 ,30 -dideoxy-50 -O(tetradecanyl)thymidine (4). Ether derivatives of FLT and AZT were synthesized by using
Mitsunobu reaction. AZT or FLT (100 mg, 0.4 mmol), tetradecanol (0.8 mmol), and TPP
(210 mg, 0.8 mmol) were dissolved in DMF (10 mL). To the reaction mixture was added
DIAD (100 mg, 0.5 mmol)). The mixture was stirred for 5 h at room temperature. The
solvent was removed in vacuo. The residue was purified by reversed-phase HPLC using
a C18 column and water/acetonitrile as the solvents as described above. The chemical
structures of compounds were confirmed by 1 H NMR and 13 C NMR (Figures S3–S6).
30 -fluoro-20 ,30 -dideoxy-50 -O-(tetradecanyl)thymidine

30 -Fluoro-20 ,30 -dideoxy-50 -O-(tetradecanyl)thymidine (3). White powder; yield (80 mg,
50%); 1 H NMR (400 MHz, CDCl3 , δ ppm): 7.52 (s, 1H, H-6), 6.19 (dd, J = 9.0 and 5.6 Hz, 1H,
H-10 ), 5.18 (dd, J = 54.0 and 4.6 Hz, 1H, H-30 ), 4.18 (d, J = 27.5 Hz, 1H, H-40 ), 3.65–3.86 (m,
4H, CH2 O, H-50 and H-500 ), 2.34–2.52 (m, 1H, H-20 ), 2.10–2.34 (m, 1H, H-200 ), 1.77 (s, 3H,
5-CH3 ), 1.37–1.55 (m, 2H, CH2 CH2 O), 1.05–1.24 (br s, 20 H, methylene envelope), 0.74 (s,
3H, CH3 ); 13 C NMR (CDCl3 , 100 MHz, δ ppm): 163.35 (C-4 C=O), 150.65 (C-2 C=O), 134.57
(C-6), 109.98 (C-5), 94.37 (d, J = 176.8 Hz, C-30 ), 86.75 (C-10 ), 85.20 (d, J = 24.2 Hz, C-40 ),
61.95 (d, J = 11.0 Hz, C-50 ), 41.28 (CH2 -O), 38.15 (d, J = 20.9 Hz, C-20 ), 32.45, 31.65, 29.38,
29.28, 29.22, 29.08, 27.31, 26.72, 25.54, 22.41 (methylene carbons), 13.81 (CH3 ), 12.94 (5-CH3 ).
HR-MS (ESI-TOF) (m/z): C24 H41 FN2 O4 : calcd. 440.305; found 441.1052 [M + H]+ .
30 -Azido-20 ,30 -dideoxy-50 -O-(tetradecanyl)thymidine (4). White powder; yield (90 mg,
50%. 1 H NMR (400 MHz, CDCl3 , δ ppm): 7.35 (s, 1H, H-6), 6.02 (t, J = 6.6 Hz, 1H, H-10 ),
4.35 (dd, J = 5.1, 11.5 Hz, 1H, H-30 ), 3.88–3.96 (m, 2H, H-50 and H-500 ), 3.85 (t, J = 7.3 Hz, 1H,
CH2 O), 3.76 (d, J = 10.6 Hz, 1H, H-40 ), 2.40–2.54 (m, 1H, H-20 ), 2.28–2.40 (m, 1H, H-200 ), 1.86
(s, 3H, 5-CH3 ), 1.53 (t, J = 6.3 Hz, 2H, CH2 CH2 O), 1.12–1.30 (br s, 20H, methylene envelope),
0.82 (t, J = 6.6 Hz, 3H, CH3 ); 13 C NMR (CDCl3 , 100 MHz, δ ppm): 163.28 (C-4 C=O),
150.72 (C-2 C=O), 134.58 (C-6), 110.29 (C-5), 87.23 (C-10 ), 84.47 (C-40 ), 61.89 (C-50 ), 59.90
(C-30 ), 41.46 (CH2 O), 37.35 (C-20 ), 31.85, 29.58, 29.53, 29.48, 29.28, 29.24, 27.51, 26.93, 22.62,
(methylene carbons), 14.05 (CH3 ), 13.22 (5-CH3 ). HR-MS (ESI-TOF) (m/z): C24 H41 N5 O4 :
calcd. 463.3159; found 464.1528 [M + H]+ .
50 -O-(Fatty acyl) ester derivatives of FLT and AZT. First, several 50 -O-(fatty acyl) ester
derivatives of FLT and AZT were synthesized at a scale of 100 mg according to the previously reported procedure [9,10] by the reaction of FLT or AZT and in situ generated
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fatty acyl chloride derivatives in the presence of 4-dimethylaminopyridine (DMAP). In the
next step, three FLT esters 30 -fluoro-20 ,30 -dideoxy-50 -O-(12-azidododecanoyl)thymidine (5),
[50 -O-(myristoyl)-30 -fluoro-20 ,30 -dideoxythymidine (6), and 30 -fluoro-20 ,30 -dideoxy-50 -O-(12thioethyldodecanoyl)thymidine (8)] were synthesized at a larger scale of 5 g and 25 g as we
previously reported [9]. Similarly, 50 -O-(fatty acyl) ester derivatives of AZT or FLT (7, 9, 10,
11, 12, 13, 16, 17, 18) were synthesized as described previously [9,10].
In general, a reaction mixture consisting of the appropriate fatty acid (1.3 mmol),
oxalyl chloride (0.25 g, 1.95 mmol), and anhydrous benzene (18 mL) was stirred at room
temperature (25 ◦ C) for 1 h. The obtained yellow solution was evaporated to dryness under
reduced pressure. The residual oil was dissolved in benzene (18 mL), and the solution was
added dropwise to an ice-cold, stirred solution consisting of the AZT (0.34 g, 1.3 mmol) or
the FLT (0.32 g, 1.3 mmol), DMAP (0.23 g, 1.9 mmol), and anhydrous benzene (18 mL) under
anhydrous conditions. The solution was stirred in an ice bath for 1 h and then refluxed in
an oil bath for about 3 h. The mixture was cooled and diluted with benzene (100 mL). The
organic solution was washed with saturated aqueous sodium carbonate (2 × 25 mL) and
then with water (2 × 25 mL). The organic layer was dried over anhydrous sodium sulfate
and was evaporated to dryness. The residue consisting of one major product was purified
by silica gel chromatography using chloroform as an eluent to yield the product. The
procedure was used for the synthesis of most of the ester analogs unless noted otherwise.
(±)-30 -Fluoro-20 ,30 -dideoxy-50 -O-(2-methoxyteradecanoyl)thymidine (13). Oil; yield
(100 mg, 90%); 1 H NMR (400 MHz, CDCl3 , δ ppm): 8.50 (s, 1H, NH), 7.31 (s, 1H, H6), 6.40 (dd, J = 9.0 and 5.6 Hz, 1H, H-10 ), 5.08–5.26 (dd, J = 52.5 and 5.5 Hz, 1H, H-30 ), 4.46
(dt, J = 25.6 and 4.0 Hz, 1H, H-40 ), 4.55 (dd, J = 12.5 and 4.1 Hz, 1H, H-50 ), 4.25 (dd, J = 12.5
and 4.1 Hz, 1H, H-500 ), 3.38 (t, J = 7.6 Hz, 1H, CHCO), 1.95 (s, 3H, 5-CH3 ), 2.55–2.72 (m,
1H, H-200 ), 2.15–2.25 (m, 1H, H-20 ), 1.70–1.80 (m, 2H, CH2 CH(OCH3 )), 1.32–1.42 (m, 2H,
CH2 CH2 CH(OCH3 )), 1.20–1.30 (br m, 18H, methylene protons), 0.87 (t, J = 7.6 Hz 3H, CH3 ).
HR-MS (ESI-TOF) (m/z): C25 H41 FN2 O6 , calcd, 484.2949; found, [M + Na]+ .
(±)-30 -Azido-20 ,30 -dideoxy-50 -O-(2-methoxyteradecanoyl)thymidine (14). Oil; yield
(100 mg, 90%); 1 H NMR (400 MHz, CDCl3 , δ ppm): 9.00 (s, 1H, N-H), 7.28 (s, 1H, H6), 6.17 (t, J = 6.2 Hz, 1H, H-10 ), 4.50 (dd, J = 12.2 and 3.7 Hz, 1H, H-50 ), 4.35 (dd, J = 12.2
and 3.7 Hz, 1H, H-500 ), 4.20 (ddd, J = 7.6, 6.2, and 5.0 Hz, 1H, H-30 ), 4.10 (ddd, = 5.0,
3.7, and 3.0 Hz, 1H, H-40 ), 3.38 (t, J = 7.6 Hz, 1H, CHCO), 3.39 (s, 3H, OCH3 ), 2.50 (ddd,
J = 13.9, 6.2, and 6.2 Hz, 1H, H-200 ), 2.37 (ddd, J = 13.9, 7.6 and 6.2 Hz, H-200 ), 1.95 (s,
3H, 5-CH3 ), 1.70–1.80 (m, 2H, CH2 CH(OCH3 )), 1.32–1.42 (m, 2H, CH2 CH2 CH(OCH3 )),
1.22–1.31 (br m, 18H, methylene protons), 0.89 (t, J = 7.6 Hz, 3H, CH3 ); HR-MS (ESI-TOF)
(m/z): C25 H41 N5 O6 , calcd, 507.3057; found, 530.6788 [M + Na]+ .
General procedure for the synthesis of 30 -fluoro-20 ,30 -dideoxy-50 -O-(3-aminopropanoyl)
thymidine (21) and 30 -fluoro-20 ,30 -dideoxy-50 -O-(12-aminododecanoyl)thymidine (22). FLT
(0.60 mmol, 150 mg), the appropriate Fmoc-amino acid (1.2 mmol), and 2-(1H-benzotriazole1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 500 mg, 1.3 mmol) were
dissolved in dry DMF (10 mL) and dry N-methylmorpholine (2 mL). The solution was
stirred overnight at room temperature. The reaction mixture was concentrated and dried
under reduced pressure to afford the crude 50 -O-Fmoc-amino acid derivatives of FLT, 19,
and 20. The crude intermediates were dissolved as such in THF (10 mL). To the reaction mixture was added piperidine (6 µL, 0.06 mmol), 1-octanethiol (10 mM solution in THF, 6 mmol,
0.6 mL). The reaction mixture was allowed to stir for 1 h at room temperature. The reaction
solution was concentrated at reduced pressure. The residue was purified with reversedphase HPLC using a C18 column and using a gradient system with water/acetonitrile as the
solvents, as described above. The chemical structures of the compounds were confirmed
by 1 H NMR and 13 C NMR as shown for compound 22 in Figures S7 and S8.
30 -Fluoro-20 ,30 -dideoxy-50 -O-(3-aminopropanoyl)thymidine (21). White powder; yield
(100 mg, 55%). HR-MS (ESI-TOF) (m/z): C13 H18 FN3 O5 : calcd. 315.1230; found 316.3369
[M + H]+ , 631.4397 [2M + H]+ .
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30 -Fluoro-20 ,30 -dideoxy-50 -O-(12-aminododecanoyl)thymidine (22). White powder; yield
(150 mg, 57%). 1 H NMR (400 MHz, CD3 OD, δ ppm): 11.38 (s, 1H, NH), 7.81–7.98 (br s,
2H, NH2 ), 7.45 (s, 1H, H-6), 6.18 (t, J = 7.9 Hz, H-10 ), 5.30 (dd, J = 53.2 and 4.2 Hz, 1H,
H-30 ), 4.15–4.36 (m, 3H, H-50 , H-500 , H-40 ), 3.15 (t, J = 8.2 Hz, 2H, CH2 NH), 2.68–2.82 (m, 2H,
CH2 CO), 2.21–2.52 (m, 4H, CH2 CH2 NH, H-20 , H-200 ), 1.76 (s, 3H, 5-CH3 ), 1.05–1.24 (br m,
16H, methylene envelope); 13 C NMR (DMSO-d6 , 100 MHz, δ ppm): 173.08 (COO), 164.07
(C-4 C=O), 150.87 (C-2 C=O), 136.08 (C-6), 110.03 (C-5), 94.38 (d, J = 175.5 Hz, C-30 ), 84.66
(C-10 ), 82.03 (d, J = 25.8 Hz, C-40 ), 63.49 (d, J = 10.6 Hz, C-50 ), 55.32, 51.54 (CH2 NH), 36.33
(d, J = 20.6 Hz, C-20 ), 33.73 (CH2 COO), 29.30, 29.25, 29.12, 28.96, 28.91, 28.84, 27.41, 26.23,
24.79, 23.51 (methylene carbons), 13.86 (5-CH3 ). HR-MS (ESI-TOF) (m/z): C22 H36 FN3 O5 :
calcd. 441.5367; found 442.1974 [M + H]+ , 883.5248 [2M + H]+ .
General procedure for the synthesis of 50 -O-(5(6)-carboxyfluorescein) derivatives of FLT
(23 and 24). FLT was attached to 5(6)-carboxyfluorescein (FAM) through β-alanine (21)
or 12-aminododecanoic acid (22) as linkers. A mixture of 5(6)-carboxyfluorescein (430
mg, 1.15 mmol), the corresponding FLT-amino acid (1.3 and 1.4, 0.29 mmoL) and HBTU
(440 mg, 1.15 mmol) was dissolved in dry DMF (10 mL) and diisopropylethylamine (DIPEA,
2 mL, 15 mmol) and stirred overnight at room temperature. The reaction mixture was
concentrated and dried under vacuum. The final compounds were purified with reversedphase HPLC using a C18 column and water/acetonitrile as the solvents, as described above.
The chemical structures of the compounds were confirmed by 1 H NMR and 13 C NMR
(Figures S9–S12).
30 -Fluoro-20 ,30 -dideoxy-50 -O-(3-(N(5(6)-carboxyfluorescein)aminopropanoyl)thymidine
(23). Yield (25 mg, 15%). 1 H NMR (400 MHz, CD3 OD, δ ppm): 8.48 (s, 0.5H, FAM-Ar-H, 5
or 6 isomer), 8.19 (d, J = 8.2 Hz, 0.5H, FAM-Ar-H, 5 or 6 isomer), 8.04, 8.13 (two dd, J = 1.6
and 8.0 Hz, 1H, FAM-Ar-H), 7.58 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 7.20–7.42 (m, 1H,
H-6, and 0.5 H FAM-Ar-H, 5 or 6 isomer), 6.96–7.05 (m, 4H, FAM-Ar-H), 6.84 (d, J = 8.9 Hz,
2H, FAM-Ar-H), 6.11 and 6.17 (two dd, J = 5.6 and 8.9, 1H, H-10 ), 5.16 and 5.23 (two dd,
J = 53.3 and 5.0 Hz, 1H, H-30 ), 4.20–4.40 (m, 3H, H-50 and H-500 , H-40 ), 3.53 and 3.64 (two t,
J = 6.5 Hz, 2H, CH2 NH), 2.10–2.74 (m, 4H, H-20 , H-200 , CH2 CO), 1.72 and 1.78 (two s, 3H,
5-CH3 ); 13 C NMR (CD3 CN, 100 MHz, δ ppm): 172.63 (COO), 172.47 (NHCO), 168.06, 165.63,
156.25 (FAM-Ar-C), 160.49 (C-4 C=O), 151.20, 151.14 (C-2 C=O), 139.64, 133.27, 131.43,
129.24, 129.60, 127.37, 127.82, 126.07 (FAM-Ar-C), 136.46, 136.52 (C-6), 116.84 (FAM-Ar-C),
113.47, 113.58 (C-5), 102.83 (FAM-Ar-C), 94.31, 94.19 (two d, J = 176.5 Hz, C-30 ), 85.53, 85.57
(C-10 ), 82.57, 82.48 (two d, J = 26.8 Hz, C-40 ), 64.13, 64.00 (two d, J = 11.2 Hz, C-50 ), 55.11,
49.09 (CH2 NH), 36.07, 35.97 (C-20 ), 33.76, 33.89 (CH2 COO), 11.95, 12.01 (5-CH3 ). HR-MS
(ESI-TOF) (m/z): C34 H28 FN3 O11 : calcd. 673.1708; found 674.5083 [M + H]+ , 1348.6951
[2M + H]+ .
30 -Fluoro-20 ,30 -dideoxy-50 -O-(12-(N(5(6)-carboxyfluorescein)aminododecanoyl)thymidine
(24). Yield (30 mg, 13%); 1 H NMR (400 MHz, CD3 OD, δ ppm): 8.45 (s, 0.5H, FAM-Ar-H,
5 or 6 isomer), 8.17 (dd, J = 1.5 and 8.0 Hz, 0.5H, FAM-Ar-H, 5, or 6 isomer), 8.10 (s, 1H,
FAM-Ar-H), 7.64 (s, 0.5H, FAM-Ar-H, 5, or 6 isomer), 7.43 (s, 1H, H-6), 7.30 (d, J = 5.1 Hz,
0.5H, FAM-Ar-H, 5 or 6 isomer), 6.76 (s, 1H, FAM-Ar-H), 6.70 (dd, J = 3.2 and 8.7 Hz, 3H,
FAM-Ar-H), 6.61 (dd, J = 2.0 and 8.7 Hz, 2H, FAM-Ar-H), 6.16–6.26 (m, 1H, H-10 ), 5.20
(dd, J = 53.4 and 4.9 Hz, 1H, H-30 ), 4.30–4.45 (m, 2H, H-50 and H-500 ), 4.19 (d, J = 5.5 and
13.6 Hz, 1H, H-40 ), 3.38 (t, J = 7.0 Hz, 2H, CH2 NH), 2.44–2.63 (m, 1H, H-20 ), 2.15–2.38 (m,
3H, CH2 CO, H-200 ), 1.83 (s, 3H, 5-CH3 ), 1.47–1.66 (m, 4H, CH2 CH2 COO, CH2 CH2 -NH),
1.05–1.24 (br m, 16H, methylene envelope); 13 C NMR (CD3 OD, 100 MHz, δ ppm): 174.85
(COO), 170.11 (NHCO), 168.34, 166.35, 155.35 (FAM-Ar-C), 163.45 (C-4 C=O), 152.29 (C-2
C=O), 142.15, 138.28, 137.40, 131.01, 129.46, 126.86, 126.08, (FAM-Ar-C), 135.12 (C-6), 115.14
(FAM-Ar-C), 112.02 (C-5), 103.72 (FAM-Ar-C), 95.32 (d, J = 177.6 Hz, C-30 ), 86.92 (C-10 ), 84.15
(d, J = 26.3 Hz, C-40 ), 64.66 (d, J = 11.7 Hz, C-50 ), 54.98, 41.40 (CH2 NH), 38.83 (d, J = 21.0 Hz,
C-20 ), 35.02 (CH2 COO), 30.77, 30.74, 30.68, 30.59, 30.54, 30.45, 30.41, 30.34, 30.26, 30.21, 28.18,
26.10 (methylene carbons), 12.81 (5-CH3 ). HR-MS (ESI-TOF) (m/z): C43 H46 FN3 O11 : calcd.
799.3116; found 800.4325 [M + H]+ .
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3.3. Physicochemical Properties (pKa, Log D., Solubility)
The physicochemical properties including pKa (9.67 ± 0.02), Log D (5.04, pH = 7.4),
and solubility were determined for 5 as a model compound.
3.3.1. pKa
The pKa for 5 was determined using dip-probe absorption spectroscopy (D-PAS) [34].
The sample was initially titrated in a fast titration between pH 1.8 and pH 12.1 at concentrations of 33–49 µM under aqueous conditions. Precipitation of the sample from the solution
was observed below approximately pH 11. The sample was subsequently titrated under
methanol–water co-solvent conditions in two triple titrations from pH 12.2 to pH 3.7 at
concentrations of 31–49 µM. The methanol ratio varied from to 25.5–50.8%. No precipitation of the sample from the solution was observed under this condition. The pKa was
determined from the spectroscopic data by the Yasuda–Shedlovsky extrapolation of the
individual obtained results. Compound 5 was found to have an aqueous pKa value of
9.67 ± 0.02 as determined by the spectroscopic method under methanol–water co-solvent
conditions.
3.3.2. Log P and Log D
The Log P of 5 was initially investigated by the pH-metric (potentiometric) method.
The sample was titrated in three triple titrations from pH 2.5 to pH 11.9 at concentrations
of 0.7–1.1 mM in various ratios of octanol/water. The results indicated high sample
lipophilicity, although the Log P could not be determined due to the apparent pKa in
octanol shifting out of the measurable range. Therefore, the Log D of 5 at pH 7.4 was
measured as 5.04 using liquid–liquid distribution chromatography. The Profiler LDA
is an isocratic chromatography system that uses an octanol-coated column with octanol
saturated mobile phases adjusted to pH 7.4. A set of standard compounds with well-known
Log D octanol values were run through the column before the samples, and the generated
retention times were used as a calibration curve to relate the retention times generated for
the sample compounds to Log D. Detection was carried out by using a UV diode array. A
multi-wavelength peak location system was used to hone in on the largest peak present in
the chromatogram. A Log D value of 5.04 was obtained, which should correspond to the
neutral Log P, in consideration of the sample pKa.
3.3.3. Solubility
Solubility for 5 was investigated by the shake-flask methodology with UV-spectroscopic
sample detection. To produce a saturated solution of 5, approximately 1 mg of solid
material was added to 10 mL of an aqueous solution, which was adjusted to pH 2.3 with
0.5 M HCl. The sample was then sonicated in an ultrasonic bath for several hours (at
room temperature) before being left to equilibrate for a period of approximately 3 days.
The supernatant was then filtered under vacuum through a 0.2 µm PVDF filter plate, and
the UV absorption spectrum of the sample was measured (after adjusting the pH of the
solution to 11.8 with 0.5 M KOH). Molar absorption coefficients of 5 were obtained at pH
11.8 for 25 µM, 50 µM, and 100 µM solutions of 5, in order to quantify the concentration
of the sample in the saturated supernatant. The UV-absorption signal (0.0039) of the
supernatant at the absorption maximum of 5 (264 nm, ε = 7650 dm3 cm−1 Mol−1 ) was close
to the detection limit of the apparatus, and the solubility value was determined as an upper
limit of <510 nM. Conjugate 5 was completely soluble in ethanol (>30 mg/mL) and the
mixture of water/methanol (60:40). However, 5 was less soluble in DMSO (~4.1 mg/mL).
3.4. Anti-HIV Assays
Anti-HIV activities of the compounds were evaluated according to the previously
reported procedure [35]. In summary, the HeLa (Human cervical carcinoma: ATCC CCL2.1) cell line was used to measure the inactivation of both the cell-free virus preparations
and virus-infected cell preparations. The cells were plated in culture plates 24 h prior to
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each experiment. Cell-free viral preparations of HIV-1 strains IIIB (lymphocytotropic strain)
and BaL (monocytotropic strain) were used for the cell-free assay. For the cell-associated
assay, the SulT1 cells were infected with IIIB virus 5 days prior to the experiment. Cell-free
virus and virus-infected cells were mixed with different compounds and diluted to make
different concentrations. The mixture was further diluted with the buffer and added to
the HeLa cells. The cells were incubated at 37 ◦ C for 48 h, stained for β-galactosidase
expression, and compared with the β-galactosidase expression from the β-gal-positive cells
in the absence of any microbicidal compound to obtain the IC50 values.
For the assessment of compounds against the wild type (WT; R5; clones = 94US3393IN
[B subtype] and 98USMSC5016 [C subtype]) and drug-resistant (clones = 4755−5 and
A17) HIV-1 clinical isolates, PHA-P stimulated cells from at least two normal donors
were pooled, diluted in fresh media, and plated in the interior wells of a 96-well roundbottom microplate. Pooling PBMCs from more than one donor was used to minimize the
variability observed between the individual donors, which results from the quantitative and
qualitative differences in HIV infection and overall response to the PHA and IL-2 of primary
lymphocyte populations. Each plate contained virus/cell control wells (cells + virus),
experimental wells (drug + cells + virus), and compound control wells (drug + media, no
cells, necessary for MTS monitoring of cytotoxicity). Test drug dilutions were prepared
in microtiter tubes, and each concentration was placed in appropriate wells. Following
the addition of the drug dilutions to the PBMCs, a predetermined dilution of virus stock
was then placed in each test well (final MOI ∼
= 0.1). Because HIV-1 is not cytopathic to
PBMCs, the same assay plate can be used for both the antiviral efficacy and cytotoxicity
measurements. Compounds were incubated with virus and cells in a 96-well format
for 6 h. The cells were then washed by removing 75% of the medium (150 µL) and
replacing it with 150 µL of fresh (no drug) medium. The plates were then centrifuged
(∼200 g) for 10 min, after which 150 µL of the medium was removed, and an additional
150 µL of fresh medium was added to each well and further incubated for 6 days or
until peak reverse transcriptase (RT) activity was detected. A microtiter plate-based RT
reaction was utilized [36]. Incorporated radioactivity (counts per minute, CPM) was
quantified using standard liquid scintillation techniques. Compound IC50 (50%, inhibition
of virus replication) was calculated using statistical software and regression analysis.
A cellular uptake study was conducted for fluorescence conjugates 23 and 24 using a
previously published procedure with minor modifications [14–16]. All of the experiments
were conducted in triplicate.
3.5. Cell Viability Study
Human T lymphoblastoid cells (CCRF-CEM, ATCC No. CCL-119) were grown to
70% confluency in a culture medium. CCRF-CEM cells were incubated with 10 µM of the
compounds and mixed with trypan blue (0.1%) to color the dead cells. The percentage of
viability was calculated by using a Cellometer Auto T.4 (Nexcelom Bioscience). The cell
viability against the vaginal cells (VK-2/E6E7) was conducted according to the previously
reported procedure [37]. The effect of conjugates on the sperm viability and mobility was
evaluated as described previously [38].
4. Conclusions
Several bifunctional 50 -O-fatty acyl derivatives of FLT were designed and synthesized
as prodrugs of FLT, a nucleoside reverse transcriptase inhibitor, and their biological activities were evaluated as anti-HIV agents and microbicides. Among all the conjugates, 5, 6,
and 8 were found to have the most active anti-HIV activity profile. Compared to AZT and
FLT, conjugates 5, 6, and 8 were active against both the cell-free virus (lymphocytotropic
and monocytotropic strains) as well as the cell-associated virus. Conjugates 5, 6, and 8
exhibited >4 and >30 times better antiviral index than FLT and AZT, respectively. The
increased inhibition by 5, 6, and 8 may be due to their increased rate of uptake, resulting
in increased intracellular level of active nucleoside achieved by the conjugate. Hydrolysis
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of the prodrug to the parent analogs was critical for the generation of anti-HIV activity.
Presumably, the intracellular hydrolysis yielded two antiviral agents, FLT and fatty acid
analog, with different enzyme targets such as RT and NMT. Conjugates 5 and 8 were active
against both the R5 and MDR strains. These conjugates have the potential to be used as
topical microbicides to prevent HIV infection during sexual activity. These data provide
insights into the more rational design of additional potent and safe anti-HIV microbicides
using the FLT or other anti-HIV nucleosides as the parent molecule. When taken together,
the results will have significant implications for the design of more potent and innovative
anti-HIV agents.
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//www.mdpi.com/article/10.3390/molecules27103352/s1. Figure S1. Cell viability assay after
3 h and 24 h of incubation of 23 and 24 with CCRF-CEM cells; Figure S2. In vitro assays for the
spermicidal activity of fatty acyl conjugates of FLT and AZT in comparison to N-9; Figure S3. 1 H NMR
of 3; Figure S4. 13 C NMR of 3; Figure S5. 1 H NMR of 4; Figure S6. 13 C NMR of 4; Figure S7. 1 H NMR
of 22; Figure S8. 13 C NMR of 22; Figure S9. 1 H NMR of 23; Figure S10. 13 C NMR of 23; Figure S11.
1 H NMR of 24; Figure S12. 13 C NMR of 24.
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